#CDK7 - Twitter Hashtag

over 1 year ago

👉👉👉Delighted to share our collaborative paper led by Dr Fiskus & Dr Bhalla @MDAndersonNews 🚨 just published in @BloodJournal in time for #ASH24 ➡️ pre-clinical efficacy of #CDK7 inhibitor- based combos vs post-MPN AML || #MPNSM #leusm #endcancer | @JAK2TheFuture @sanamloghavi

doctorpemm's tweet photo. 👉👉👉Delighted to share our collaborative paper led by Dr Fiskus & Dr Bhalla @MDAndersonNews 🚨 just published in @BloodJournal in time for #ASH24 ➡️ pre-clinical efficacy of #CDK7 inhibitor- based combos vs post-MPN AML || #MPNSM #leusm #endcancer | @JAK2TheFuture @sanamloghavi https://t.co/32kEhHqa6u

2

52

8

4

3K

Science Translational Medicine @ScienceTM

over 1 year ago

Scientists successfully alleviated both acute and chronic #RheumatoidArthritis in mice by using inhibitors of #CDK7 to target the transcription of inflammatory genes in #macrophages, according to new research from a team at @HSpecialSurgery. @RogatskyLab https://t.co/aOx8W8Bb8O

ScienceTM's tweet photo. Scientists successfully alleviated both acute and chronic #RheumatoidArthritis in mice by using inhibitors of #CDK7 to target the transcription of inflammatory genes in #macrophages, according to new research from a team at @HSpecialSurgery. @RogatskyLab https://t.co/aOx8W8Bb8O https://t.co/ipnXvBxg89

0

12

3

2K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

about 2 years ago

New📰| Selective #CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive #BreastCancer | Full text in @CCR_AACR. @CriGuarducci @RMJesel @GShapiroMDPhD @AlbertGrinshpun ➡️https://t.co/PxIBLa7gyd

DFCI_BreastOnc's tweet photo. New📰| Selective #CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive #BreastCancer | Full text in @CCR_AACR. @CriGuarducci @RMJesel @GShapiroMDPhD @AlbertGrinshpun
➡️https://t.co/PxIBLa7gyd https://t.co/whY4D1v3mn

1

26

18

8

3K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

over 2 years ago

New study now out in Clinical Cancer Research: Selective #CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive #BreastCancer. @CriGuarducci @RMJesel @GShapiroMDPhD https://t.co/PxIBLa6IIF

DFCI_BreastOnc's tweet photo. New study now out in Clinical Cancer Research: Selective #CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive #BreastCancer.
@CriGuarducci @RMJesel @GShapiroMDPhD
https://t.co/PxIBLa6IIF https://t.co/3rbjjwdY6K

0

44

20

5

3K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

over 2 years ago

Rinath Jeselsohn, MD (@RMJesel) presented a talk on #CDK7 inhibition in ER+ #BreastCancer: Mechanisms of action and reversal of CDK4/6 inhibitor resistance in today's @df_hcc Breast Cancer Program Research Retreat.

DFCI_BreastOnc's tweet photo. Rinath Jeselsohn, MD (@RMJesel) presented a talk on #CDK7 inhibition in ER+ #BreastCancer: Mechanisms of action and reversal of CDK4/6 inhibitor resistance in today's @df_hcc Breast Cancer Program Research Retreat. https://t.co/QHf2hmgWgJ

0

7

1

0

811

Ruth Keri @RuthKeri2

about 3 years ago

Delighted to see our latest paper on #CDK7 and chromosome instability in #breastcancer in press @jbiolchem! Congrats to @KatrinaPiemonte and Bryan Webb! @cwrumstp @CCLRI @caseccc #bcsm https://t.co/KxE4z07ddg

RuthKeri2's tweet photo. Delighted to see our latest paper on #CDK7 and chromosome instability in #breastcancer in press @jbiolchem! Congrats to @KatrinaPiemonte and Bryan Webb! @cwrumstp @CCLRI @caseccc #bcsm https://t.co/KxE4z07ddg https://t.co/cKnLbOrtU1

5

40

6

0

4K

Biomedicines MDPI @Biomed_MDPI

almost 4 years ago

👉Paper Recommendation: Identification of #CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations https://t.co/DOdHa8rrLG via @Biomed_MDPI Topic: #Pharmacoinformatics

Biomed_MDPI's tweet photo. 👉Paper Recommendation:
Identification of #CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations
https://t.co/DOdHa8rrLG
via @Biomed_MDPI

Topic: #Pharmacoinformatics https://t.co/MNsegC82kA

0

2

0

Corbin Kaylor @CorbinKaylor0

over 4 years ago

Can I get a #CDK7 👀

1

3

0

Corbin Kaylor @CorbinKaylor0

over 4 years ago

Grinding #CDK7

0

2

1

0

Dr. Iván R. González

@Dr_Ivanoncologo

over 4 years ago

"Study of #Samuraciclib a first-in-class, oral, selective inhibitor of #CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative Breast Cancer" interesante revisión de la Dra. Denisse Lee #SABCS @FUCAMM @OncoAlert @BCTrials

Dr_Ivanoncologo's tweet photo. "Study of #Samuraciclib a first-in-class, oral, selective inhibitor of #CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative Breast Cancer" interesante revisión de la Dra. Denisse Lee #SABCS @FUCAMM @OncoAlert @BCTrials https://t.co/0W7zuC1Ufl

0

6

3

0

Matteo Lambertini, MD PhD @matteolambe

over 4 years ago

General session 3 at #SABCS21: interesting preliminary data with #samuraciclib an oral selective #CDK7 inhibitor combined with #fulvestrant in #HR+/#HER2- advanced #BreastCancer patients progressing on CDK4/6 inhibitor-based first-line therapy @OncoAlert #bcsm @SABCSSanAntonio

matteolambe's tweet photo. General session 3 at #SABCS21: interesting preliminary data with #samuraciclib an oral selective #CDK7 inhibitor combined with #fulvestrant in #HR+/#HER2- advanced #BreastCancer patients progressing on CDK4/6 inhibitor-based first-line therapy

@OncoAlert #bcsm @SABCSSanAntonio https://t.co/8I5zaHF984

0

38

7

1

0

MedChemExpress

@MedChemExpress

over 4 years ago

#IV361 is an orally active and selective #CDK7 inhibitor (Ki≤50 nM). IV-361 has #anticancer activity. #drugdiscovery. https://t.co/H5lJm1zPTP

MedChemExpress's tweet photo. #IV361 is an orally active and selective #CDK7 inhibitor (Ki≤50 nM). IV-361 has #anticancer activity. #drugdiscovery. https://t.co/H5lJm1zPTP https://t.co/0ZT20rPdaC

0

3

1

0

Syros Pharma @SyrosPharma

almost 5 years ago

At the upcoming #ESMO21 Congress, we plan to provide updates from our ongoing dose-escalation trial with SY-5609. Learn more about our SY-5609 approach to inhibit #CDK7 in select solid #tumors https://t.co/WW33XCo16q

SyrosPharma's tweet photo. At the upcoming #ESMO21 Congress, we plan to provide updates from our ongoing dose-escalation trial with SY-5609. Learn more about our SY-5609 approach to inhibit #CDK7 in select solid #tumors
https://t.co/WW33XCo16q https://t.co/NOaVnXwv05

0

3

2

0

J of Cell Signaling @SignalingJ

over 5 years ago

#CDK7 is a central regulator of cell cycle, gene transcription. Impact on genomic instability, cancer immunity. Selective CDK7 inhibitor, disrupts cell-cycle progression, induces #DNA replication, genome instability in #SCLC simultaneously triggering immune-response #signaling.

SignalingJ's tweet photo. #CDK7 is a central regulator of cell cycle, gene transcription. Impact on genomic instability, cancer immunity. Selective CDK7 inhibitor, disrupts cell-cycle progression, induces #DNA replication, genome instability in #SCLC simultaneously triggering immune-response #signaling. https://t.co/xrkYq0ybWc

0

3

0

IIFL Capital Services Limited @iiflcapital

over 5 years ago

Dr Reddy's soars 2% as US-based Exelixis in-licenses wholly-owned subsidiary's Aurigene's novel CDK7 inhibitor https://t.co/1aQ0PaXMUV #DrReddy #CDK7

0

2

0

Corbin Kaylor @CorbinKaylor0

over 5 years ago

Premiering My Finale #7RC response it's not the best but I tried <3 #CDK7 @7eamCo @MrMari0s @Jolta_ @DigsOnly_ @Wippeys @UnluckyBrah @MetaHits @Zinky_7 https://t.co/VGfvKWU25w

2

19

3

0